Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 and PT001 PK/Safety in Japanese Healthy Subjects
NCT02196714Phase 1Completed
- Sponsor
- Pearl Therapeutics
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glycopyrronium and formoterol fumarate in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Primary endpoints: Maximum Plasma Concentration at Day 1, Area Under the Curve 0-12 hours at Day 1 and 7 more. Started Jul 2014; status: completed.
02
Drugs
glycopyrroniumformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02196714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196714.